Functional and oncological outcomes following more than three consecutive surgical resections for multiple relapses of initially grade 2 IDH-mutated gliomas.


Journal

Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000

Informations de publication

Date de publication:
28 Oct 2024
Historique:
received: 10 08 2024
accepted: 16 10 2024
medline: 28 10 2024
pubmed: 28 10 2024
entrez: 28 10 2024
Statut: epublish

Résumé

Second and third surgeries were demonstrated as safe and efficient in recurrent diffuse low-grade glioma (LGG). Here, the feasibility of more than 3 resections is investigated. Patients who underwent 4 or 5 operations for recurrent initially WHO grade 2 IDH-mutated gliomas were consecutively selected. Twenty-three operations were performed in five patients (all males, mean age 27.2 ± 4 years). Three patients underwent 5 surgeries and two patients underwent 4 surgeries. Twelve procedures (52%) were achieved with awake mapping, including all 4th and 5th operations but one. Repeat electrical mapping detected changes of the cortical maps between at least two awake surgeries in 4 patients. No patients experienced permanent neurological impairment (KPS score ≥ 80 in all cases). The patients returned to work after 22 surgeries among 23 (95.6%). There were 3 oligodendrogliomas and 2 astrocytomas (4 gliomas became malignant at fourth or fifth operation). Although the preoperative tumor volume significantly increased before the fourth (p = 0.026) and fifth operation (p = 0.003) compared with the first operation, there was no significant difference between the residual tumor volume after the fourth or fifth resection versus the first one. The mean delay was 10.6 ± 3.9 years before chemotherapy and 15.4 ± 3.4 years before radiotherapy (one patient never received adjuvant treatment after 21.5 years). The mean follow-up duration was 18.3 ± 3.1 years since the first surgery (2.3 ± 1.8 years since the last surgery). Three patients were still alive at last follow-up. This is the first series showing that to reoperate beyond three times is feasible with a low functional risk and a long survival in multiple LGG recurrences, with the use of awake mapping in 87.5% of 4th and 5th surgeries.

Sections du résumé

BACKGROUND BACKGROUND
Second and third surgeries were demonstrated as safe and efficient in recurrent diffuse low-grade glioma (LGG). Here, the feasibility of more than 3 resections is investigated.
METHODS METHODS
Patients who underwent 4 or 5 operations for recurrent initially WHO grade 2 IDH-mutated gliomas were consecutively selected.
RESULTS RESULTS
Twenty-three operations were performed in five patients (all males, mean age 27.2 ± 4 years). Three patients underwent 5 surgeries and two patients underwent 4 surgeries. Twelve procedures (52%) were achieved with awake mapping, including all 4th and 5th operations but one. Repeat electrical mapping detected changes of the cortical maps between at least two awake surgeries in 4 patients. No patients experienced permanent neurological impairment (KPS score ≥ 80 in all cases). The patients returned to work after 22 surgeries among 23 (95.6%). There were 3 oligodendrogliomas and 2 astrocytomas (4 gliomas became malignant at fourth or fifth operation). Although the preoperative tumor volume significantly increased before the fourth (p = 0.026) and fifth operation (p = 0.003) compared with the first operation, there was no significant difference between the residual tumor volume after the fourth or fifth resection versus the first one. The mean delay was 10.6 ± 3.9 years before chemotherapy and 15.4 ± 3.4 years before radiotherapy (one patient never received adjuvant treatment after 21.5 years). The mean follow-up duration was 18.3 ± 3.1 years since the first surgery (2.3 ± 1.8 years since the last surgery). Three patients were still alive at last follow-up.
CONCLUSIONS CONCLUSIONS
This is the first series showing that to reoperate beyond three times is feasible with a low functional risk and a long survival in multiple LGG recurrences, with the use of awake mapping in 87.5% of 4th and 5th surgeries.

Identifiants

pubmed: 39465448
doi: 10.1007/s00701-024-06321-6
pii: 10.1007/s00701-024-06321-6
doi:

Substances chimiques

Isocitrate Dehydrogenase EC 1.1.1.41

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

425

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Références

Alhalabi OT, Dao Trong P et al (2024) Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: a risk-benefit analysis. J Neurooncol 167(2):245–255. https://doi.org/10.1007/s11060-024-04595-5
doi: 10.1007/s11060-024-04595-5 pubmed: 38334907 pmcid: 11023957
Alvarez de Eulate-Beramendi S, Rigau V, Taillandier L, Duffau H (2014) Delayed leptomeningeal and subependymal seeding after multiple surgeries for supratentorial diffuse low-grade gliomas in adults. J Neurosurg 120:833–839. https://doi.org/10.3171/2013.10.JNS131512
doi: 10.3171/2013.10.JNS131512 pubmed: 24286144
Blonski M, Obara T, Brzenczek C et al (2022) Initial PCV chemotherapy followed by Radiotherapy is Associated with a prolonged response but late neurotoxicity in 20 diffuse low-Grade Glioma patients. Front Oncol 12:827897. https://doi.org/10.3389/fonc.2022.827897
doi: 10.3389/fonc.2022.827897 pubmed: 35311144 pmcid: 8931287
Boccuni L, Abellaneda-Pérez K, Martín-Fernández J et al (2023) Neuromodulation-induced prehabilitation to leverage neuroplasticity before brain tumor surgery: a single-cohort feasibility trial protocol. Front Neurol 2:1243857
doi: 10.3389/fneur.2023.1243857
Capelle L, Fontaine D, Mandonnet E et al (2013) Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases. J Neurosurg 118:1157–1168. https://doi.org/10.3171/2013.1.JNS121
doi: 10.3171/2013.1.JNS121 pubmed: 23495881
Capo G, Skrap M, Guarracino I et al (2020) Cognitive functions in repeated glioma surgery. Cancers (Basel) 12:1077. https://doi.org/10.3390/cancers12051077
doi: 10.3390/cancers12051077 pubmed: 32357421
Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quiñones-Hinojosa A (2010) Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 112:10–17. https://doi.org/10.3171/2008.10.JNS08608
doi: 10.3171/2008.10.JNS08608 pubmed: 19361270
Darlix A, Deverdun J, Menjot de Champfleur N et al (2017) IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. J Neurooncol 133:37–45. https://doi.org/10.1007/s11060-017-2421-0
doi: 10.1007/s11060-017-2421-0 pubmed: 28434111
Darlix A, Rigau V, Fraisse J, Gozé C, Fabbro M, Duffau H (2020) Postoperative follow-up for selected diffuse low-grade gliomas with WHO grade III/IV foci. Neurology 94(8):e830–e841. https://doi.org/10.1212/WNL.0000000000008877
doi: 10.1212/WNL.0000000000008877 pubmed: 31969465
De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS (2012) Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 30:2559–2565. https://doi.org/10.1200/JCO.2011.38.4818
doi: 10.1200/JCO.2011.38.4818 pubmed: 22529254
Di Perri D, Jmil S, Lawson TM et al (2023) Health-related quality of life and cognitive failures in patients with lower-grade gliomas treated with radiotherapy. Cancer Radiother 7:219–224. https://doi.org/10.1016/j.canrad.2022.10.004
doi: 10.1016/j.canrad.2022.10.004
Douw L, Klein M, Fagel SS et al (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8:810–818. https://doi.org/10.1016/S1474-4422(09)70204-2
doi: 10.1016/S1474-4422(09)70204-2 pubmed: 19665931
Duffau H (2015) Stimulation mapping of white matter tracts to study brain functional connectivity. Nat Rev Neurol 11:255–265
doi: 10.1038/nrneurol.2015.51 pubmed: 25848923
Duffau H (2016) Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir (Wien) 158:51–58. https://doi.org/10.1007/s00701-015-2621-32
doi: 10.1007/s00701-015-2621-32 pubmed: 26530708
Duffau H (2017) Diffuse Low-Grade Gliomas in Adults. 2nd ed. Duffau Ed, 2017. Springer International Publishing: Imprint: Springer. https://doi.org/10.1007/978-3-319-55466-2
Duffau H (2021) Brain connectomics applied to oncological neuroscience: from a traditional surgical strategy focusing on glioma topography to a meta-network approach. Acta Neurochir (Wien) 163:905–917. https://doi.org/10.1007/s00701-021-04752-z
doi: 10.1007/s00701-021-04752-z pubmed: 33564906
Duffau H (2021) New Philosophy, clinical pearls, and methods for Intraoperative Cognition Mapping and monitoring à La Carte in Brain Tumor patients. Neurosurgery 88(5):919–930. https://doi.org/10.1093/neuros/nyaa363
doi: 10.1093/neuros/nyaa363 pubmed: 33463689
Duffau H (2021) Introducing the concept of brain metaplasticity in glioma: how to reorient the pattern of neural reconfiguration to optimize the therapeutic strategy. J Neurosurg 136:613–617. https://doi.org/10.3171/2021.5.JNS211214
doi: 10.3171/2021.5.JNS211214 pubmed: 34624858
Duffau H (2022) A personalized longitudinal strategy in low-Grade Glioma patients: predicting oncological and neural interindividual variability and its changes over years to think one step ahead. J Pers Med 12:1621. https://doi.org/10.3390/jpm12101621
doi: 10.3390/jpm12101621 pubmed: 36294760 pmcid: 9604939
Duffau H (2022) Repeated Awake Surgical Resection(s) for recurrent diffuse low-Grade gliomas: why, when, and how to reoperate? Front Oncol 12:947933. https://doi.org/10.3389/fonc.2022.947933
doi: 10.3389/fonc.2022.947933 pubmed: 35865482 pmcid: 9294369
Duffau H, Filippi M (2024) Moving towards a connectomic view of neuro-oncology. Lancet Neurol 23:655–656. https://doi.org/10.1016/S1474-4422(23)00291-0
doi: 10.1016/S1474-4422(23)00291-0 pubmed: 38876732
Ferracci FX, Michaud K, Duffau H (2019) The landscape of postsurgical recurrence patterns in diffuse low-grade gliomas. Crit Rev Oncol Hematol 138:148–155. https://doi.org/10.1016/j.critrevonc.2019.04.009
doi: 10.1016/j.critrevonc.2019.04.009 pubmed: 31092371
Fukuya Y, Ikuta S, Maruyama T et al (2019) Tumor recurrence patterns after surgical resection of intracranial low-grade gliomas. J Neurooncol 144:519–528. https://doi.org/10.1007/s11060-019-03250-8
doi: 10.1007/s11060-019-03250-8 pubmed: 31363908
Hamdan N, Duffau H (2022) Extending the multistage surgical strategy for recurrent initially low-grade gliomas: functional and oncological outcomes in 31 consecutive patients who underwent a third resection under awake mapping. J Neurosurg 136:1035–1044. https://doi.org/10.3171/2021.3.JNS21264
doi: 10.3171/2021.3.JNS21264 pubmed: 34507287
Herbet G, Maheu M, Costi E, Lafargue G, Duffau H (2016) Brain neuroplastic map mapping neuroplastic potential in brain-damaged patients. Brain 139:829–844. https://doi.org/10.1093/brain/awv394
doi: 10.1093/brain/awv394 pubmed: 26912646
Herbet G, Duffau H, Mandonnet E (2024) Predictors of cognition after glioma surgery: connectotomy, structure-function phenotype, plasticity. Brain 4:awae093. https://doi.org/10.1093/brain/awae093 . (Online ahead of print)
doi: 10.1093/brain/awae093
Hervey-Jumper SL, Zhang Y, Phillips JJ et al (2023) Interactive effects of Molecular, Therapeutic, and patient factors on outcome of diffuse low-Grade Glioma. J Clin Oncol 41:2029–2042. https://doi.org/10.1200/JCO.21.02929
doi: 10.1200/JCO.21.02929 pubmed: 36599113 pmcid: 10082290
Jakola AS, Bouget D, Reinertsen I et al (2020) Spatial distribution of malignant transformation in patients with low-grade glioma. J Neurooncol 146:373–380. https://doi.org/10.1007/s11060-020-03391-1
doi: 10.1007/s11060-020-03391-1 pubmed: 31915981 pmcid: 6971181
Latini F, Fahlström M, Hesselager G, Zetterling M, Ryttlefors M (2020) Differences in the preferential location and invasiveness of diffuse low-grade gliomas and their impact on outcome. Cancer Med 9:5446–5458. https://doi.org/10.1002/cam4.3216
doi: 10.1002/cam4.3216 pubmed: 32537906 pmcid: 7402839
Lemaitre AL, Herbet G, Ng S, Moritz-Gasser S, Duffau H (2022) Cognitive preservation following awake mapping-based neurosurgery for low-grade gliomas: a longitudinal, within-patient design study. Neuro-Oncol 24:781–793. https://doi.org/10.1093/neuonc/noab275
doi: 10.1093/neuonc/noab275 pubmed: 34850187
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the Central Nervous System: a Summary. Neurooncology 23:1231–1251
Mandonnet E, Delattre J, Tanguy M et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53:524–528. https://doi.org/10.1002/ana.10528
doi: 10.1002/ana.10528 pubmed: 12666121
Mandonnet E, De Witt Hamer P, Poisson I et al (2015) Initial experience using awake surgery for glioma: oncological, functional, and employment outcomes in a consecutive series of 25 cases. Neurosurgery 76:382–389. https://doi.org/10.1227/NEU.0000000000000644 . (discussion 389)
doi: 10.1227/NEU.0000000000000644 pubmed: 25621981
Ng S, Duffau H (2023) Brain plasticity profiling as a key support to therapeutic decision-making in low-Grade Glioma Oncological Strategies. Cancers 15(14):3698. https://doi.org/10.3390/cancers15143698
doi: 10.3390/cancers15143698 pubmed: 37509359 pmcid: 10378506
Ng S, Valdes PA, Moritz-Gasser S, Lemaitre AL, Duffau H, Herbet G (2023) Intraoperative functional remapping unveils evolving patterns of cortical plasticity. Brain 146:3088–3100. https://doi.org/10.1093/brain/awad116
doi: 10.1093/brain/awad116 pubmed: 37029961
Obara T, Blonski M, Brzenczek C et al (2020) Adult diffuse low-Grade gliomas: 35-Year experience at the Nancy France Neurooncology Unit. Front Oncol 10:574679. https://doi.org/10.3389/fonc.2020.574679
doi: 10.3389/fonc.2020.574679 pubmed: 33194684 pmcid: 7656991
Picart T, Herbet G, Moritz-Gasser S, Duffau H (2019) Iterative Surgical resections of diffuse glioma with Awake Mapping: how to deal with cortical plasticity and connectomal constraints? Neurosurgery 85:105–116. https://doi.org/10.1093/neuros/nyy218
doi: 10.1093/neuros/nyy218 pubmed: 30010996
Ribeiro L, Ng S, Duffau H (2022) Recurrent insular low-grade gliomas: factors guiding the decision to reoperate. J Neurosurg 138:1216–1226. https://doi.org/10.3171/2022.9.JNS221286
doi: 10.3171/2022.9.JNS221286 pubmed: 36308479
Roelz R, Strohmaier D, Jabbarli R et al (2016) Residual tumor volume as best outcome predictor in low Grade Glioma - A Nine-Years Near-Randomized Survey of surgery vs. Biopsy Sci Rep 6:32286. https://doi.org/10.1038/srep32286
doi: 10.1038/srep32286 pubmed: 27574036
Rossi M, Gay L, Ambrogi F et al (2021) Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas. Neuro Oncol 23:812–826. https://doi.org/10.1093/neuonc/noaa225
doi: 10.1093/neuonc/noaa225 pubmed: 33049063
Sarubbo S, Tate M, De Benedictis A et al (2020) Mapping critical cortical hubs and white matter pathways by direct electrical stimulation: an original functional atlas of the human brain. NeuroImage 205:116237. https://doi.org/10.1016/j.neuroimage.2019.116237
doi: 10.1016/j.neuroimage.2019.116237 pubmed: 31626897
Shofty B, Haim O, Costa M et al (2020) Impact of repeated operations for progressive low-grade gliomas. Eur J Surg Oncol 46:2331–2337. https://doi.org/10.1016/j.ejso.2020.07.013
doi: 10.1016/j.ejso.2020.07.013 pubmed: 32771251
Southwell DG, Hervey-Jumper SL, Perry DW, Berger MS (2016) Intraoperative mapping during repeat awake craniotomy reveals the functional plasticity of adult cortex. J Neurosurg 124:1460–1469. https://doi.org/10.3171/2015.5.JNS142833
doi: 10.3171/2015.5.JNS142833 pubmed: 26544767
Zattra CM, Zhang DY, Broggi M et al (2019) Repeated craniotomies for intracranial tumors: is the risk increased? Pooled analysis of two prospective, institutional registries of complications and outcomes. J Neurooncol 142:49–57. https://doi.org/10.1007/s11060-018-03058-y
doi: 10.1007/s11060-018-03058-y pubmed: 30474767
Zinsz A, Pouget C, Rech F et al (2024) The role of [18 F]FDOPA PET as an adjunct to conventional MRI in the diagnosis of aggressive glial lesions. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-024-06720-y

Auteurs

Anissa Nassihi (A)

Department of Neurosurgery, University of Rouen, Rouen, France.

Hugues Duffau (H)

Department of Neurosurgery, Gui de Chauliac Hospital, Montpellier University Medical Center, 80 Avenue Augustin Fliche, Montpellier, 34295, France. h-duffau@chu-montpellier.fr.
Institute of Functional Genomics, Team "Plasticity of Central Nervous System, Stem Cells and Low-grade gliomas," INSERM U1191, University of Montpellier, Montpellier, France. h-duffau@chu-montpellier.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH